SYNTHON HISPANIA SL
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about SYNTHON HISPANIA SL
Live alerts from global media, monitored by Business Radar
(news-medical.net)
Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals
ADCs are used for a new type of targeted therapy that consists of a specific anti-cancer antibody or antibody fragment linked to a potent anti-cancer therapeutic.
Read more
(fiercebiotech.com)
Synthon taps Dutch blood donor group for CD47 program |
The organization that runs the Netherlands' network of blood donors, Sanquin, knows a thing or two about hematology, and it turns out also cancer. | Dutch biotech Synthon joined the race to develop cancer immunotherapies targeting the hot new immune checkpoint CD47.
Read more